Clinical Trial Update: A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics study of tafluprost ophthalmic solution (0.0015%) in pediatric patients with glaucoma or ocular hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• Zioptan (tafluprost)

Snippet

Sponsor: Santen Oy | Conditions: Glaucoma, Ocular Hypertension | Phase 1 | Status: COMPLETED